Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan and Limertinib in Locally Advanced EGFR-mutant NSCLC
NCT07323056Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, limertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Started Jan 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecanlimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07323056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07323056.